| pubmed-article:19920112 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19920112 | lifeskim:mentions | umls-concept:C0007600 | lld:lifeskim |
| pubmed-article:19920112 | lifeskim:mentions | umls-concept:C1512505 | lld:lifeskim |
| pubmed-article:19920112 | lifeskim:mentions | umls-concept:C0728747 | lld:lifeskim |
| pubmed-article:19920112 | lifeskim:mentions | umls-concept:C0683598 | lld:lifeskim |
| pubmed-article:19920112 | lifeskim:mentions | umls-concept:C2247782 | lld:lifeskim |
| pubmed-article:19920112 | pubmed:issue | 23 | lld:pubmed |
| pubmed-article:19920112 | pubmed:dateCreated | 2009-12-2 | lld:pubmed |
| pubmed-article:19920112 | pubmed:abstractText | Trastuzumab is a monoclonal antibody targeted to the Her2 receptor and approved for treatment of Her2-positive breast cancer. Among patients who initially respond to trastuzumab therapy, resistance typically arises within 1 year. BT/Her(R) cells are trastuzumab-resistant variants of Her2-positive BT474 breast cancer cells. The salient feature of BT/Her(R) cells is failure to downregulate phosphoinositide 3-kinase/Akt signaling on trastuzumab binding. The current work addresses the mechanism of sustained signaling in BT/Her(R) cells, focusing on the protein kinase A (PKA) pathway. | lld:pubmed |
| pubmed-article:19920112 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19920112 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19920112 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19920112 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19920112 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19920112 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19920112 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19920112 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19920112 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19920112 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19920112 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19920112 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19920112 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19920112 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19920112 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19920112 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:19920112 | pubmed:issn | 1078-0432 | lld:pubmed |
| pubmed-article:19920112 | pubmed:author | pubmed-author:KaneSusan ESE | lld:pubmed |
| pubmed-article:19920112 | pubmed:author | pubmed-author:SomloGeorgeG | lld:pubmed |
| pubmed-article:19920112 | pubmed:author | pubmed-author:LauSean KSK | lld:pubmed |
| pubmed-article:19920112 | pubmed:author | pubmed-author:GuLongL | lld:pubmed |
| pubmed-article:19920112 | pubmed:author | pubmed-author:LoeraSofiaS | lld:pubmed |
| pubmed-article:19920112 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:19920112 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:19920112 | pubmed:volume | 15 | lld:pubmed |
| pubmed-article:19920112 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19920112 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19920112 | pubmed:pagination | 7196-206 | lld:pubmed |
| pubmed-article:19920112 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:19920112 | pubmed:meshHeading | pubmed-meshheading:19920112... | lld:pubmed |
| pubmed-article:19920112 | pubmed:meshHeading | pubmed-meshheading:19920112... | lld:pubmed |
| pubmed-article:19920112 | pubmed:meshHeading | pubmed-meshheading:19920112... | lld:pubmed |
| pubmed-article:19920112 | pubmed:meshHeading | pubmed-meshheading:19920112... | lld:pubmed |
| pubmed-article:19920112 | pubmed:meshHeading | pubmed-meshheading:19920112... | lld:pubmed |
| pubmed-article:19920112 | pubmed:meshHeading | pubmed-meshheading:19920112... | lld:pubmed |
| pubmed-article:19920112 | pubmed:meshHeading | pubmed-meshheading:19920112... | lld:pubmed |
| pubmed-article:19920112 | pubmed:meshHeading | pubmed-meshheading:19920112... | lld:pubmed |
| pubmed-article:19920112 | pubmed:meshHeading | pubmed-meshheading:19920112... | lld:pubmed |
| pubmed-article:19920112 | pubmed:meshHeading | pubmed-meshheading:19920112... | lld:pubmed |
| pubmed-article:19920112 | pubmed:meshHeading | pubmed-meshheading:19920112... | lld:pubmed |
| pubmed-article:19920112 | pubmed:meshHeading | pubmed-meshheading:19920112... | lld:pubmed |
| pubmed-article:19920112 | pubmed:meshHeading | pubmed-meshheading:19920112... | lld:pubmed |
| pubmed-article:19920112 | pubmed:meshHeading | pubmed-meshheading:19920112... | lld:pubmed |
| pubmed-article:19920112 | pubmed:meshHeading | pubmed-meshheading:19920112... | lld:pubmed |
| pubmed-article:19920112 | pubmed:meshHeading | pubmed-meshheading:19920112... | lld:pubmed |
| pubmed-article:19920112 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19920112 | pubmed:articleTitle | Protein kinase A activation confers resistance to trastuzumab in human breast cancer cell lines. | lld:pubmed |
| pubmed-article:19920112 | pubmed:affiliation | Division of Tumor Cell Biology, City of Hope Comprehensive Cancer Center, Duarte, California 91107, USA. | lld:pubmed |
| pubmed-article:19920112 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19920112 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:19920112 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
| entrez-gene:5566 | entrezgene:pubmed | pubmed-article:19920112 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:19920112 | lld:entrezgene |
